Skip to main content
SpringerLink
Log in

Pulmonary Arterial Hypertension Secondary to Anorexigens and Other Drugs and Toxins

  • Chapter
  • First Online:
Textbook of Pulmonary Vascular Disease

Abstract

Several drugs and toxins have been shown to be associated with the development of pulmonary vascular hypertension. Pulmonary hypertension (PH) related to these factors has been classified as primary PH (PPH), currently referred to as idiopathic pulmonary arterial hypertension, because its morphological findings, clinical manifestations, hemodynamic measures, and pathological changes were reported to be similar to those of PPH. In 1998, a clinical classification of PH was proposed, the “Evian classification,” which was updated in 2003. According to the revised clinical classification of PH, this disease with identifiable risk factors is called “pulmonary arterial hypertension (PAH) associated with drugs and toxins”. However, some drugs can be associated with pulmonary veno-occlusive disease (PVOD), persistent PH of the newborn (PPHN), and newly recognized systemic disease, in which the histopathological findings are characterized by pulmonary arteriopathy with medial hypertrophy of muscular and elastic arteries, dilation and intimal atheromas of elastic pulmonary arteries, and right ventricular hypertrophy. Plexogenic arteriopathy can be seen with the exception of PAH of persistent fetal circulation. The identification of drugs and toxins as risk factors for PH poses a great challenge to both the physician and the epidemiologist. Drugs and toxins are categorized according to the strength of their association with PH and the probability of causal role. Table 1 summarizes the drugs and toxins considered in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 349.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Simonneau G, Galiè N, Rubin LJ et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12S

    PubMed  Google Scholar 

  2. Gurtner HP (1985) Aminorex and pulmonary hypertension. A review. Cor Vasa 27:160–171

    PubMed  CAS  Google Scholar 

  3. Follath F, Burkart F, Schweizer W (1971) Drug-induced pulmonary hypertension? Br Med J 1:265–266

    PubMed  CAS  Google Scholar 

  4. Greiser E (1973) Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension. Internist (Berl) 14:437–442

    CAS  Google Scholar 

  5. Olivari MT (1991) Primary pulmonary hypertension. Am J Med Sci 302:185–198

    PubMed  CAS  Google Scholar 

  6. Loogen F, Worth H, Schwan G, Goeckenjan G, Lösse B, Horstkotte D (1985) Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 27:111–124

    PubMed  CAS  Google Scholar 

  7. Kay JM, Smith P, Heath D (1971) Aminorex and the pulmonary circulation. Thorax 26:262–270

    PubMed  CAS  Google Scholar 

  8. Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA (2000) Recreational use of aminorex and pulmonary hypertension. Chest 118:1496–1497

    PubMed  CAS  Google Scholar 

  9. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT (1981) Pulmonary hypertension and fenfluramine. Br Med J 283:881–883

    CAS  Google Scholar 

  10. Pouwels HM, Smeets JL, Cheriex EC, Wouters EF (1990) Pulmonary hypertension and fenfluramine. Eur Respir J 3:606–607

    PubMed  CAS  Google Scholar 

  11. McMurray J, Bloomfield P, Miller HC (1986) Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J 292:239–240

    CAS  Google Scholar 

  12. Fotiadis I, Apostolou T, Koukoulas A, Michelacakis N, Kremastinos D (1991) Fenfluramine-induced irreversible pulmonary hypertension. Postgrad Med J 67:776–777

    PubMed  CAS  Google Scholar 

  13. Atanassoff PG, Weiss BM, Schmid ER, Tornic M (1992) Pulmonary hypertension and dexfenfluramine. Lancet 339:436

    PubMed  CAS  Google Scholar 

  14. Roche N, Labrune S, Braun JM, Huchon GJ (1992) Pulmonary hypertension and dexfenfluramine. Lancet 339:436–437

    PubMed  CAS  Google Scholar 

  15. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G (1993) Primary pulmonary hypertension and fenfluramine use. Br Heart J 70:537–541

    PubMed  CAS  Google Scholar 

  16. Abenhaim L, Moride Y, Brenot F et al (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335:609–616

    PubMed  CAS  Google Scholar 

  17. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC (1997) Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 337:602–606

    PubMed  CAS  Google Scholar 

  18. Strother J, Fedullo P, Yi ES, Masliah E (1999) Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. Arch Pathol Lab Med 123:539–540

    PubMed  CAS  Google Scholar 

  19. Tomita T, Zhao Q (2002) Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. Chest 121:649–652

    PubMed  Google Scholar 

  20. Connolly HM, Crary JL, McGoon MD et al (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581–588

    PubMed  CAS  Google Scholar 

  21. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L (2000) Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117:870–874

    PubMed  CAS  Google Scholar 

  22. Walker AM, Langleben D, Korelitz JJ et al (2006) Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 152:521–526

    PubMed  CAS  Google Scholar 

  23. Humbert M, Sitbon O, Chaouat A et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030

    PubMed  Google Scholar 

  24. Souza R, Humbert M, Sztrymf B et al (2008) Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 31:343–348

    PubMed  CAS  Google Scholar 

  25. Rich S, Shillington A, McLaughlin V (2003) Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. Am J Cardiol 92:1366–1368

    PubMed  CAS  Google Scholar 

  26. Hervé P, Launay JM, Scrobohaci ML et al (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249–254

    PubMed  Google Scholar 

  27. Friström S, Airaksinen MM, Halmekoski J (1977) Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivatives. Acta Pharmacol Toxicol 41:218–224

    Google Scholar 

  28. Zheng Y, Russell B, Schmierer D, Laverty R (1997) The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice. J Pharm Pharmacol 49:89–96

    PubMed  CAS  Google Scholar 

  29. Celada P, Martín F, Artigas F (1994) Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 55:1237–1243

    PubMed  CAS  Google Scholar 

  30. Redmon B, Raatz S, Bantle JP (1997) Valvular heart disease ­associated with fenfluramine-phentermine. N Engl J Med 337:1773–1774

    PubMed  CAS  Google Scholar 

  31. Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP (2000) Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 85:913–915

    PubMed  CAS  Google Scholar 

  32. Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100:869–875

    PubMed  CAS  Google Scholar 

  33. Lee SL, Wang WW, Fanburg BL (2001) Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J 15:1324–1325

    PubMed  CAS  Google Scholar 

  34. Blanpain C, Le Poul E, Parma J et al (2003) Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 60:518–528

    PubMed  CAS  Google Scholar 

  35. Dempsie Y, Morecroft I, Welsh DJ et al (2008) Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 117:2928–2937

    PubMed  CAS  Google Scholar 

  36. Weir EK, Reeve HL, Huang JM et al (1996) Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216–2220

    PubMed  CAS  Google Scholar 

  37. Machado RD, Pauciulo MW, Thomson JR et al (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68:92–102

    PubMed  CAS  Google Scholar 

  38. Thomson JR, Machado RD, Pauciulo MW et al (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 37:741–745

    PubMed  CAS  Google Scholar 

  39. Humbert M, Deng Z, Simonneau G et al (2002) BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20:518–523

    PubMed  CAS  Google Scholar 

  40. Chaouat A, Coulet F, Favre C et al (2004) Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 59:446–448

    PubMed  CAS  Google Scholar 

  41. Weir EK, Obreztchikova M, Hong Z (2008) Fenfluramine: riddle or Rosetta stone? Eur Respir J 31:232–235

    PubMed  CAS  Google Scholar 

  42. Cameron J, Waugh L, Loadsman T, White P, Radford DJ (1984) Possible association of pulmonary hypertension with an anorectic drug. Med J Aust 140:595–597

    PubMed  CAS  Google Scholar 

  43. Nall KC, Rubin LJ, Lipskind S, Sennesh JD (1991) Reversible pulmonary hypertension associated with anorexigen use. Am J Med 91:97–99

    PubMed  CAS  Google Scholar 

  44. Hagiwara M, Tsuchida A, Hyakkoku M et al (2000) Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. Jpn Circ J 64:218–221

    PubMed  CAS  Google Scholar 

  45. Barst RJ, Abenhaim L (2004) Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 90:e42

    PubMed  CAS  Google Scholar 

  46. Thomas SH, Butt AY, Corris PA et al (1995) Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J 74:660–663

    PubMed  CAS  Google Scholar 

  47. Abramowicz MJ, Van Haecke P, Demedts M, Delcroix M (2003) Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 22:560–562

    PubMed  CAS  Google Scholar 

  48. No authors listed (2004) Hidden amphetamines: from smoking cessation to diabetes. Prescrire Int 13:18–20

    Google Scholar 

  49. Boutet K, Frachon I, Jobic Y et al (2009) Fenfluramine-like ­cardiovascular side effects of benfluorex. Eur Respir J 33:684–688

    PubMed  CAS  Google Scholar 

  50. Rafel Ribera J, Casañas Muñoz R, Anguera Ferrando N, Batalla Sahún N, Castro Cels A, Pujadas Capmany R (2003) Valvular heart disease associated with benfluorex. Rev Esp Cardiol 56:215–216

    PubMed  Google Scholar 

  51. Evrard F, Dupuis M, Muller T, Jacquerye P (2008) Isolated pulmonary hypertension and pergolide. Rev Neurol 164:278–279

    PubMed  CAS  Google Scholar 

  52. Hong Z, Smith AJ, Archer SL et al (2005) Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation 112:1494–1499

    PubMed  Google Scholar 

  53. Fahlén M, Bergman H, Helder G, Rydén L, Wallentin I, Zettergren L (1973) Phenformin and pulmonary hypertension. Br Heart J 35:824–828

    PubMed  Google Scholar 

  54. Kleiger RE, Boxer M, Ingham RE, Harrison DC (1976) Pulmonary hypertension in patients using oral contraceptives. A report of six cases. Chest 69:143–147

    PubMed  CAS  Google Scholar 

  55. Townend JN, Roberts DH, Jones EL, Davies MK (1992) Fatal pulmonary venoocclusive disease after use of oral contraceptives. Am Heart J 124:1643–1644

    PubMed  CAS  Google Scholar 

  56. Morse JH, Horn EM, Barst RJ (1999) Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest 116:847

    PubMed  CAS  Google Scholar 

  57. Martinez-Taboada VM, Rodriguez-Valverde V, Gonzalez-Vilchez F, Armijo JA (2004) Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. Rheumatology 43:1451–1453

    PubMed  CAS  Google Scholar 

  58. Jochmann N, Kiecker F, Borges AC et al (2005) Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 3:26

    PubMed  Google Scholar 

  59. Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH (2003) Vascular events associated with alpha interferon therapy. Leuk Lymphoma 44:471–475

    PubMed  CAS  Google Scholar 

  60. Dawson A, Elias DJ, Rubenson D et al (1996) Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med 125:901–904

    PubMed  CAS  Google Scholar 

  61. Belmatoug N, Launay O, Carbon C (1998) Pulmonary hypertension in type 1 Gaucher’s disease. Comité d’Evaluation du Traitement de la Maladie de Gaucher. Lancet 352:240

    PubMed  CAS  Google Scholar 

  62. Younis TH, Alam A, Paplham P, Spangenthal E, McCarthy P (2003) Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol 121:191–192

    PubMed  Google Scholar 

  63. Antonioli E, Nozzoli C, Gianfaldoni G et al (2005) Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol 16:1849–1850

    PubMed  CAS  Google Scholar 

  64. Hattori Y, Shimoda M, Okamoto S, Satoh T, Kakimoto T, Ikeda Y (2005) Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol 128:885–887

    PubMed  Google Scholar 

  65. Lafaras C, Mandala E, Verrou E et al (2008) Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol 19:1765–1769

    PubMed  CAS  Google Scholar 

  66. Bentur L, Cullinane C, Wilson P, Greenberg M, O’Brodovich H, Silver MM (1991) Fatal pulmonary arterial occlusive vascular disease following chemotherapy in a 9-month-old infant. Hum Pathol 22:1295–1298

    PubMed  CAS  Google Scholar 

  67. Vaksmann G, Nelken B, Deshildre A, Rey C (2002) Pulmonary arterial occlusive disease following chemotherapy and bone marrow transplantation for leukaemia. Eur J Pediatr 161:247–249

    PubMed  Google Scholar 

  68. Joselson R, Warnock M (1983) Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 14:88–91

    PubMed  CAS  Google Scholar 

  69. Knight BK, Rose AG (1985) Pulmonary veno-occlusive disease after chemotherapy. Thorax 40:874–875

    PubMed  CAS  Google Scholar 

  70. Waldhorn RE, Tsou E, Smith FP, Kerwin DM (1984) Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 12:394–396

    PubMed  CAS  Google Scholar 

  71. Vansteenkiste JF, Bomans P, Verbeken EK, Nackaerts KL, Demedts MG (2001) Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer 31:83–85

    PubMed  CAS  Google Scholar 

  72. Gagnadoux F, Capron F, Lebeau B (2002) Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 36:213–215

    PubMed  CAS  Google Scholar 

  73. Lombard CM, Churg A, Winokur S (1987) Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 92:871–876

    PubMed  CAS  Google Scholar 

  74. Trobaugh-Lotrario AD, Greffe B, Deterding R, Deutsch G, Quinones R (2003) Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review. J Pediatr Hematol Oncol 25:405–409

    PubMed  Google Scholar 

  75. Rose AG (1983) Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma. Case reports. S Afr Med J 64:636–638

    PubMed  CAS  Google Scholar 

  76. Swift GL, Gibbs A, Campbell IA, Wagenvoort CA, Tuthill D (1993) Pulmonary veno-occlusive disease and Hodgkin’s lymphoma. Eur Respir J 6:596–598

    PubMed  CAS  Google Scholar 

  77. Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF (1996) Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant 18:755–760

    PubMed  CAS  Google Scholar 

  78. Seguchi M, Hirabayashi N, Fujii Y et al (2000) Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 69:177–179

    PubMed  CAS  Google Scholar 

  79. Troussard X, Bernaudin JF, Cordonnier C et al (1984) Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax 39:956–957

    PubMed  CAS  Google Scholar 

  80. Hackman RC, Madtes DK, Petersen FB, Clark JG (1989) Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 47:989–992

    PubMed  CAS  Google Scholar 

  81. Kuga T, Kohda K, Hirayama Y et al (1996) Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol 64:143–150

    PubMed  CAS  Google Scholar 

  82. Williams LM, Fussell S, Veith RW, Nelson S, Mason CM (1996) Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Chest 109:1388–1391

    PubMed  CAS  Google Scholar 

  83. Shankar S, Choi JK, Dermody TS, Head DR, Bunin N, Iannone R (2004) Pulmonary hypertension complicating bone marrow transplantation for idiopathic myelofibrosis. J Pediatr Hematol Oncol 26:393–397

    PubMed  Google Scholar 

  84. Capewell SJ, Wright AJ, Ellis DA (1984) Pulmonary veno-occlusive disease in association with Hodgkin’s disease. Thorax 39:554–555

    PubMed  CAS  Google Scholar 

  85. Kramer MR, Estenne M, Berkman N et al (1993) Radiation-induced pulmonary veno-occlusive disease. Chest 104:1282–1284

    PubMed  CAS  Google Scholar 

  86. Walsh-Sukys MC, Tyson JE, Wright LL et al (2000) Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105:14–20

    PubMed  CAS  Google Scholar 

  87. Manchester D, Margolis HS, Sheldon RE (1976) Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol 126:467–469

    PubMed  CAS  Google Scholar 

  88. Dalens B, Dechelotte P, Gaulme J, Raynaud EJ (1981) Maternal treatment with indomethacin and severe neonatal pulmonary hypertension. Arch Fr Pediatr 38:261–265

    PubMed  CAS  Google Scholar 

  89. Loe SM, Sanchez-Ramos L, Kaunitz AM (2005) Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol 106:173–179

    PubMed  Google Scholar 

  90. Herget J, Hampl V, Povýsilová V, Slavík Z (1995) Long-term effects of prenatal indomethacin administration on the pulmonary circulation in rats. Eur Respir J 8:209–215

    PubMed  CAS  Google Scholar 

  91. Levin DL, Fixler DE, Morriss FC, Tyson J (1978) Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr 92:478–483

    PubMed  CAS  Google Scholar 

  92. Silvani P, Camporesi A (2007) Drug-induced pulmonary hypertension in newborns: a review. Curr Vasc Pharmacol 5:129–133

    PubMed  CAS  Google Scholar 

  93. Reefhuis J, Rasmussen SA, Friedman JM (2006) Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 354:2188–2190

    PubMed  CAS  Google Scholar 

  94. Källén B, Olausson PO (2008) Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17:801–806

    PubMed  Google Scholar 

  95. Fornaro E, Li D, Pan J, Belik J (2007) Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 176:1035–1040

    PubMed  CAS  Google Scholar 

  96. Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL (1993) Pulmonary hypertension associated with long-term inhalation of “crank” methamphetamine. Chest 104:614–616

    PubMed  CAS  Google Scholar 

  97. Chin KM, Channick RN, Rubin LJ (2006) Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 130:1657–1663

    PubMed  CAS  Google Scholar 

  98. Rothman RB, Baumann MH (2007) Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. Chest 132:1412–1413

    PubMed  Google Scholar 

  99. Murray RJ, Smialek JE, Golle M, Albin RJ (1989) Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest 96:1050–1053

    PubMed  CAS  Google Scholar 

  100. Russell LA, Spehlmann JC, Clarke M et al (1992) Pulmonary hypertension in female crack users. Am Rev Respir Dis 145:A717

    Google Scholar 

  101. Collins E, Hardwick RJ, Jeffery H (1989) Perinatal cocaine intoxication. Med J Aust 150(331–332):334

    Google Scholar 

  102. Devathasan G, Low D, Teoh PC, Wan SH, Wong PK (1984) Complications of chronic glue (toluene) abuse in adolescents. Aust N Z J Med 14:39–43

    PubMed  CAS  Google Scholar 

  103. Kay JM (1994) Dietary pulmonary hypertension. Thorax 49:S33–S38

    PubMed  Google Scholar 

  104. Posada de la Paz M, Philen RM, Borda AI (2001) Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 23:231–247

    PubMed  CAS  Google Scholar 

  105. Castro García M, Posada de la Paz M, Díaz de Rojas F, Abaitua Borda I, Aonso Gordo JM, Tabuenca Oliver JM (1984) Pulmonary hypertension after toxic rapeseed oil ingestion. J Am Coll Cardiol 4:443

    PubMed  Google Scholar 

  106. Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L (1993) Toxic oil syndrome: a long-term follow-up of a cohort of 332 patients. Medicine 72:285–295

    PubMed  CAS  Google Scholar 

  107. Abaitua Borda I, Philen RM, Posada de la Paz M et al (1998) Toxic oil syndrome mortality: the first 13 years. Int J Epidemiol 27:1057–1063

    PubMed  CAS  Google Scholar 

  108. Gómez-Sánchez MA, Mestre de Juan MJ, Gómez-Pajuelo C, López JI, Díaz de Atauri MJ, Martínez-Tello FJ (1989) Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study. Chest 95:325–331

    PubMed  Google Scholar 

  109. Kilbourne EM (1992) Eosinophilia-myalgia syndrome: coming to grips with a new illness. Epidemiol Rev 14:16–36

    PubMed  CAS  Google Scholar 

  110. Tazelaar HD, Myers JL, Drage CW, King TE Jr, Aguayo S, Colby TV (1990) Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest 97:1032–1036

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors thank M. Humbert for his helpful comments and advice.

Author information

Authors and Affiliations

  1. Paris Santé Cochin, La-ser, 26 rue d’Ulm, Paris, 75005, France

    Kim Bouillon

Authors
  1. Kim Bouillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yola Moride
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lamiae Bensouda-Grimaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lucien Abenhaim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim Bouillon .

Editor information

Editors and Affiliations

  1. Departments of Medicine, COMRB Rm. 3131 (MC 719), University of Illinois at Chicago, 909 South Wolcott Avenue, Chicago, 60612, Illinois, USA

    Jason X. -J. Yuan

  2. 310 Admin.Office Building (MC 672), University of Illinois at Chicago, 1737 W. Polk Street, Suite 310, Chicago, 60612, Illinois, USA

    Joe G.N. Garcia

  3. Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, 92093-0623, California, USA

    John B. West

  4. Dept. Pulmonary & Critical Care Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, Massachusetts, USA

    Charles A. Hales

  5. Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Ave., Chicago, 60637, Illinois, USA

    Stuart Rich

  6. Department of Medicine, University of Chicago School of Medicine, 5841 S. Maryland Ave., Chicago, 60637, Illinois, USA

    Stephen L. Archer

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bouillon, K., Moride, Y., Bensouda-Grimaldi, L., Abenhaim, L. (2011). Pulmonary Arterial Hypertension Secondary to Anorexigens and Other Drugs and Toxins. In: Yuan, JJ., Garcia, J., West, J., Hales, C., Rich, S., Archer, S. (eds) Textbook of Pulmonary Vascular Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-87429-6_73

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-87429-6_73

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-87428-9

  • Online ISBN: 978-0-387-87429-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation